Published in final edited form as:

J Am Chem Soc. 2013 August 14; 135(32): 11680–11683. doi:10.1021/ja402453k.

Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry

Jonathan D. White[†], Maire F. Osborn[†], Alan D. Moghaddam, Lindsay E. Guzman, Michael M. Haley, and Victoria J. DeRose^{*}

Department of Chemistry and Institute of Molecular Biology, University of Oregon, Eugene, OR 97403-1253 USA

Abstract

Despite the broad use of platinum-based chemotherapeutics, identification of their full range of cellular targets remains a significant challenge. In order to identify, visualize, and isolate cellular targets of Pt(II) complexes, we have modified the chemotherapeutic drug picoplatin with an azide moiety for subsequent click reactivity. The new compound picazoplatin readily binds DNA and RNA oligonucleotides and undergoes facile post-labeling click reactions to alkyne-fluorophore conjugates. Pt-fluorophore click reactions in ribosomal RNA purified from drug-treated *S. cerevisiae* demonstrate its potential for future *in vivo* efforts.

Platinum (II) compounds comprise up to 50–70% of anticancer treatment regimes in use today.¹ Unlike other classes of common therapeutics such as anti-biotics, however, a molecular-level understanding of the specific targets of Pt(II) drugs is lacking.² Pt(II) drugs preferentially target purine nucleobases, and drug binding to genomic DNA is an accepted cause of downstream apoptotic signaling.³ Less than 10% of Pt (in the case of cisplatin) accumulates within genomic DNA,⁴ and questions remain regarding additional targets that could impact cytotoxicity and resistance. A facile and sensitive method for drug target analysis would greatly aid such investigations.

One synthetic-based strategy for target identification involves modifying Pt(II) complexes to contain sterically small bioorthogonally reactive handles. Chemical transformations at this handle (such as reaction with a fluorophore) following drug treatment would allow for accurate Pt localization *in vivo* or subsequent purification of cellular targets.^{2c} Post-treatment labeling circumvents problems associated with using compounds modified with bulky or charged fluorophores, which may not accurately represent cellular processing of the native drug.^{2d} An ideal candidate for post-treatment labeling is the azide-alkyne dipolar cycloaddition, the prototypical click reaction.⁵ Click chemistry has been broadly used for

Corresponding Author. derose@uoregon.edu.

[†]These authors contributed equally to this work.

ASSOCIATED CONTENT

Supporting Information Available: Experimental procedures, syntheses of complexes, ¹H & ¹⁹⁵Pt NMR, complete MALDI, and high-resolution mass spectrometry data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes

The authors declare no competing financial interests.

localization and functional studies of modified bio-molecules, including proteins and nucleic acids.^{6,7} Despite the importance of Pt(II) compounds in the-rapeutics and catalysis, applications of click reactions on Pt(II) complexes have been limited.⁸ Click reactions have been used as a synthetic route to generate libraries of Pt-based therapeutics^{8d-f} and for fluorescent post-labeling of a monofunctional Pt(II)-acridine derivative.⁹ Our goal is to modify small bifunctional Pt(II) reagents such as cisplatin and related compounds (Figure 1) for post-treatment analysis.

Here, we report the synthesis of the novel azide-functionalized Pt(II) complex **1** and present DNA oligonucleotide binding and subsequent click reactivity with alkyne-modified fluorophores (Figures 2 and 3). We extend these studies to show *in vitro* labeling of a structured RNA oligonucleotide (Figure 4) and *in vivo* treatment and post-labeling of yeast ribosomal RNA (Figure 5). This tandem Pt binding and post-modification technique enables visualization and quantification of the cellular targets of Pt(II) compounds, and may be broadly applicable towards identification of other metal-ion based drug targets.

We designed complex **1** with the azide-functionalized 2-picoline ligand, similar to the well-known complex picoplatin (Figure 1a).¹⁰ Since Pt(II) is capable of catalyzing hydroamination and other undesirable side reactions with alkynes,¹¹ the azide-functionalized complex remained the initial focus of this work. In addition, organoazide complexes of Pt, where the azide moieties are connected through organic linkers and not directly bound to the Pt center, are known compounds.¹² Furthermore, an azide-Pt(II) click reagent allows for the future use of non-linear, ring-strained alkynes and thus copper-free click chemistry.¹³ The steric hindrance provided by the 2-methyl group of picoplatin and its derivatives slows the kinetics of substitution reactions on Pt and is an important effector of therapeutic activity.^{10,14} The presence of the 2-methyl substituent also prevents the formation of *dipicoline* adducts and generally yields cleaner syntheses compared to other asymmetrically substituted cisplatin derivatives.¹⁵ Complex **1** was synthesized and fully characterized by ¹H and ¹⁹⁵Pt NMR, IR, and HRMS (see Supporting Information).

Cisplatin, picoplatin, and similar Pt compounds bind readily to 5'-GG-3'-containing short DNA oligonucleotides and hairpin structures.^{3a,c,16} Binding of **1** to double-stranded DNA and click labeling were analyzed by dPAGE (Figure 2). Resolution between the denatured strands is clearly observed, and reaction with two-fold excess **1** (4 h, 37 °C) results in a new band corresponding to Pt-bound T₆GGT₅ (Figure 1b, left and center lanes) in yields similar to those observed with the parent compound picoplatin (not shown). Reaction of the Pt-bound oligonucleotide with an alkyne fluorophore (dansyl propargylamine)¹⁷ in the presence of CuI (4 h, 50 °C) results in fluorescent labeling of the Pt-bound species (Figure 2b, right lane). Observation of the expected click product with a single-stranded T₆GGT₅ construct was confirmed by MALDI mass spectrometry (Figure 2c).¹⁸ The observed Pt-bound species (Figure 2c, black) shifts to a higher m/z as predicted from cy-cloaddition of the dansyl fluorophore (Figure 2c, blue). The click reaction efficiency appears to be high, as the Pt-bound peak disappears completely in the clicked (blue) spectrum.

Additional work examining nonspecific interactions between the dansyl alkyne fluorophore and the terminal azide of the Pt-bound DNA scaffold was performed with a pyrimidine rich

DNA hairpin (Figure 3a).¹⁶ This sequence was selected to minimize potential Pt interstrand crosslink formation between hairpins (as was occasionally observed for single-stranded T₆GGT₅, data not shown). A Pt-bound species is not resolved under these gel conditions, but fluorescence detection of the subsequent click reaction clearly identifies a platinated species. No non-specific fluorescent labeling is observed under Cu-free conditions (Figure 3, lane 1) following the reaction of the hairpin with two-fold excess **1** (18 h, 37 °C). Proficient fluorescent labeling of the **1**-bound GG DNA hairpin is observed with either CuI-catalyzed (Figure 3, lanes 2–3) or CuSO₄-catalyzed click protocols (Figure 3, lanes 4–5) following incubation at 50 °C for 1 h.

The presence of Pt(II) lesions in cellular RNAs and their potential downstream consequences have become an increasingly important consideration given the many regulatory roles of RNA in essential cell processes.¹⁹ Recent studies in our laboratory have demonstrated that in *S. cerevisiae*, cisplatin-derived Pt species accumulate to a significantly greater extent in RNA versus DNA, with ribosomal RNA acting as a *de facto* cellular Pt sponge.^{19a} In context of *E. coli*²⁰ and *S. cerevisiae*^{19a} ribosomal RNA, specific Pt binding sites have been identified within the small ribosomal subunit. Pt adducts are also observed in the sarcin-ricin loop (SRL), a universally conserved exogenous loop essential for elongation factor binding and GTP-dependent translocation (unpublished data).²¹ To establish potential for using Pt-click reagents on cellular RNA, we investigated the interaction and click reactivity of **1** on a model SRL RNA construct (Figure 4).

The sensitivity of unmodified (i.e., 2'-OH) RNA species towards degradation by Cu-mediated chemistry has previously limited studies of click reactions with RNA sequences like the SRL in the absence of protective ligands such as TBTA or under O₂-free conditions.²² We have independently observed significant degradation of our SRL RNA construct under various Cu-catalyzed click conditions (not shown). Recent work has demonstrated that trace amounts of acetonitrile stabilize free Cu(I) in aqueous solution while still facilitating efficient cycloaddition catalysis.²² Here, we demonstrate substantial click product formation from picazoplatin-bound RNA in the presence of 0.6% v/v acetonitrile (Figure 4 and S7). Lanes 1–3 of Figure 4 show that the SRL RNA is stable in up to 0.8 molar equivalents of Cu(I). In lanes 4–7, a supershift demonstrates Pt-adduct formation following RNA treatment with four-fold excess **1** (18 h, 37 °C). Notably, lanes 6 and 7 demonstrate efficient Cu(I)-catalyzed click labeling to dansyl alkyne fluorophore (1 h, 50 °C). Thus, post-treatment labeling by click chemistry is also successful for the analysis of RNA-Pt adducts.

To assess the feasibility of identifying cellular pica-zoplatin-bound species, we extracted and labeled ribosomal RNA from **1**-treated *S. cerevisiae* with Alexa Fluor 488 DIBO alkyne (Figure 5). Lane 1 contains a 200 nucleotide RNA marker. Lanes 2–4 contain 5.8S ribosomal RNA isolated from cells treated for 6 h with 0 (Lane 2), 250 or 500 μM picazoplatin (Lanes 3,4) and reacted with an excess of alkyne fluorophore (18 h, 37°C). Lane 2 indicates the absence of nonspecific labeling. Lanes 3 and 4 clearly demonstrate increasing picazoplatin accumulation on 5.8S rRNA *in vivo* and successful alkyne fluorophore labeling to an intact azide. These studies show the potential for analysis of Pt(II)

drug targets and/or fluorescent imaging of Pt trafficking *in vivo* in fixed and permeabilized cells.

In summary, we report the successful synthesis of picazoplatin, an azide-containing picoplatin derivative for Pt-bound drug target analysis by click chemistry. Picazoplatin readily binds DNA oligonucleotides and undergoes high-yielding click reactions with alkyne fluorophores. Moreover, successful fluorophore labeling via acetonitrile-assisted click reactions were demonstrated on an RNA mimic of the ribosomal sarcin-ricin loop construct, demonstrating viability of this approach in the presence of unmodified (i.e. 2'-OH-intact) RNA. Preliminary *in vivo* applications of this technique identified the 5.8S ribosomal RNA as a cellular Pt(II) drug target.

Future applications of Pt-click reactions could include the isolation, purification, and identification of *in vivo* targets of Pt(II) therapeutics using various alkyne-functionalized scaffolds. Reversal of Pt covalent linkages could be achieved by saturation with thiourea,^{18a} releasing Pt-bound constituents for analysis via high-throughput sequencing, proteomics, or other analytical methods.^{2c} The ability of Pt(II) compounds to crosslink RNA and RNA-protein complexes²³ suggests additional applications in RNA and ribonucleoproteins structure-function analyses. Such efforts towards using Pt-mediated click chemistry to isolate and quantify Pt-bound species are currently underway in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Science Foundation for support of this research (CHE-1153147) as well as support in the form of an instrumentation grant (CHE-0923589). We gratefully acknowledge Dr. Robert Spitale at Stanford University for advice on *in vivo* RNA click chemistry protocols.

REFERENCES

1. (a) Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. Chem. Eur. J. 2010; 16:7064–7077. [PubMed: 20533453] (b) Dyson PJ, Sava G. Dalton Trans. 2006; 16:1929–1933. [PubMed: 16609762]
2. (a) Sava G, Jaouen G, Hillard EA, Bergamo A. Dalton Trans. 2012; 41:8226–8234. [PubMed: 22614531] (b) Casini A, Reedijk J. Chem. Sci. 2012; 3:3135–3144.(c) Guggenheim ER, Xu D, Zhang CX, Chang PV, Lippard SJ. Chem. Bio. Chem. 2009; 10:141–157.(d) Wexselblatt E, Yavin E, Gibson D. Inorg. Chim. Acta. 2012; 393:75–83.
3. (a) Wang D, Lippard SJ. Nat. Rev. Drug Discov. 2005; 4:307–320. [PubMed: 15789122] (b) Boulikas T, Vougiouka M. Oncol. Rep. 2003; 10:1663–1682. [PubMed: 14534679] (c) Jamieson ER, Lippard SJ. Chem. Rev. 1999; 99:2467–2498. [PubMed: 11749487]
4. (a) Akaboshi M, Kawai K, Ujono Y, Takada S, Miyahara T. Jpn. J. Can. Res. 1994; 85:106–111.(b) Akaboshi M, Kawai K, Maki H, Akuta K, Ujono Y, Miyahara T. Jpn. J. Can. Res. 1992; 83:522–526.(c) De-Conti RC, Toftness BR, Lange RC, Creasy WA. Cancer Res. 1973; 33:1310–1315. [PubMed: 4515709]
5. Kolb HC, Finn MG, Sharpless KB. Angew. Chem. Int. Ed. 2004; 40:2004–2021.
6. (a) Jewett JC, Bertozzi CR. Chem. Soc. Rev. 2010; 39:1272–1279. [PubMed: 20349533] (b) Sletten EM, Bertozzi CR. Angew. Chem. 2009; 48:6974–6998. [PubMed: 19714693]

7. (a) El-Sagheer AH, Brown T. *Acc. Chem. Res.* 2012; 45:1258–1267. [PubMed: 22439702] (b) Jao CY, Salic A. *PNAS.* 2008; 105:15779–15784. [PubMed: 18840688]
8. (a) Struthers H, Mindt TL, Schibli R. *Dalton Trans.* 2010; 39:675–696. [PubMed: 20066208] (b) Clough MC, Zeits PD, Bhuvanesh N, Gladysz JA. *Organometallics.* 2012; 31:5231–5234. (c) Stengel I, Strassert CA, Plummer EA, Chien C-H, De Cola L, Bäuerle P. *Eur. J. Inorg. Chem.* 2012:1795–1809. (d) Ding S, Qiao X, Kucera GL, Bierbach U. *J. Med. Chem.* 2012; 55:10198–10203. [PubMed: 23074987] (e) Urankar D, Košmrlj J. *Inorg. Chim. Acta.* 2010; 363:3817–3822. (f) Struthers H, Mindt TL, Schibli R. *Dalton Trans.* 2010; 39:675–696. [PubMed: 20066208]
9. Ding S, Qiao X, Suryadi J, Marrs GS, Kucera GL, Bierbach U. *Angew. Chem. Int. Ed.* 2013; 52:3350–3354.
10. (a) Kelland L. *Nat. Rev. Cancer.* 2007; 7:573–584. [PubMed: 17625587] (b) Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. *Clin. Canc. Res.* 1997; 3:2063–2074.
11. Belluco U, Bertani R, Michelin RA, Mozzon MJ. *Organomet. Chem.* 2000; 600:37–55.
12. Kane SA, Lippard S. *J. Biochem.* 1996; 35:2180–2188.
13. Sletten EM, Bertozzi CR. *Acc. Chem. Res.* 2011; 44:666–676. [PubMed: 21838330]
14. (a) Chen Y, Guo Z, Parsons S, Sadler PJ. *Chem. Eur. J.* 1998; 4:672–676. (b) Chen Y, Guo Z, Parkinson JA, Sadler PJ. *Dalton Trans.* 1998:3577–3585. (c) Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. *J. Inorg. Biochem.* 1999; 77:111–115. [PubMed: 10626362]
15. Battle AR, Choi R, Hibbs DE, Hambley TW. *Inorg. Chem.* 2006; 45:6317–6322. [PubMed: 16878941]
16. Chen Y, Parkinson JA, Guo Z, Brown T, Sadler PJ. *Angew. Chem. Int. Ed.* 1999; 38:2060–2063.
17. Bolletta F, Fabbri D, Lombardo M, Prodi L, Trombini C, Zaccheroni N. *Organometallics.* 1996; 15:2415–2417.
18. (a) Chapman EG, DeRose VJ. *J. Am. Chem. Soc.* 2010; 132:1946–1952. [PubMed: 20099814] (b) Hostetter AA, Chapman EG, DeRose VJ. *J. Am. Chem. Soc.* 2009; 131:9250–9257. [PubMed: 19566097]
19. (a) Hostetter AA, Osborn MF, DeRose VJ. *ACS Chem. Bio.* 2012; 7:218–225. [PubMed: 22004017] (b) Guan L, Disney M. *ACS Chem. Bio.* 2012; 7:73–86. [PubMed: 22185671] (c) Hedman HK, Kirpeker F, Elmroth SK. *J. Am. Chem. Soc.* 2011; 133:11977–11984. [PubMed: 21721571]
20. Keshab R, Chow CS. *Chem. Commun.* 2009:107–109.
21. (a) Shi X, Khade PK, Sanbonmatsu KY, Joseph S. *J. Mol. Biol.* 2012; 419:125–138. [PubMed: 22459262] (b) Moazed D, Robertson JM, Moller HF. *Nature.* 1988; 334:362–364. [PubMed: 2455872]
22. (a) Paredes E, Das SR. *Bioorg. Med. Chem. Lett.* 2012; 12:5313–5316. [PubMed: 22818972] (b) Paredes E, Das SR. *Chem. Bio. Chem.* 2011; 12:125–131.
23. Dufour E, Reinbolt J, Castroviejo M, Ehresmann B, Litvak S, Tarrago-Litvak L, Andreola M-L. *J. Mol. Biol.* 1999; 285:1339–1346. [PubMed: 9917377]

Figure 1.

(a) The anticancer drugs cisplatin and picoplatin, with the novel picoplatin analogue **1**, picazoplatin. (b) Reaction scheme of biomolecule-bound picazoplatin clicking to a dansyl fluorophore.

Figure 2.

(a) DNA duplex with picazoplatin (**1**) bound and labeled with dansyl alkyne fluorophore. (b) dPAGE analysis showing the denatured complementary strands (left) and higher molecular weight Pt-bound species (center). Click reaction with the fluorophore results in fluorescence of the Pt-DNA band under UV light (right). (c) MALDI mass spectra of Pt-DNA (black) and Pt-DNA-click product (blue) showing the change in mass upon binding **1** and reacting with the fluorophore. Expected m/z of 4301.7 and 4590.8 compared to the observed 4300.03 and 4587.3, respectively. Conditions are outlined in the Supporting Information.

Figure 3.

(a) DNA hairpin with **1** bound and labeled with the alkyne fluorophore. (b) dPAGE analysis showing fluorescent labeling of DNA hairpin by Cu-catalyzed click chemistry. Lane 1 contains *non*platinated DNA hairpin and shows no nonspecific DNA-fluorophore interaction. Lanes 2–5 contain platinated DNA under varying click condition sets (Supporting Information), all of which show successful DNA-fluorophore labeling.

Figure 4.

Fluorescent labeling of Pt-bound RNA SRL hairpin by click chemistry. (a) RNA SRL hairpin. Potential Pt binding sites are indicated by starred nucleotides. (b) Lanes 1–3: non-platinated RNA is stable in click reaction conditions with 0.4 (triangle) or 0.8 equivalents (circle) CuI. Lanes 4–7: SRL RNA treated with 4 equivalents **1** shows increasing yields of fluorophore labeling following click reactions with 0.4 (lane 6) and 0.8 (lane 7) equivalents CuI and the dansyl alkyne. Conditions are given in the Supporting Information.

Figure 5.

Fluorescent labeling by click chemistry of ribosomal RNA from **1**-treated *S. cerevisiae*. Lane 1 contains a 200 nucleotide RNA marker. Lanes 2–4 contain 5.8S ribosomal RNA (approx. 160 nucleotides) extracted from *S. cerevisiae* treated with 0, 250, or 500 μM picazoplatin and clicked to an excess of Alexa Fluor 488 DIBO alkyne (18 h, 37 °C). Proficient fluorescent labeling of the 5.8S rRNA is observed from *in vivo* **1**-treated samples. Conditions are given in the Supporting Information.